About Tango Therapeutics, Inc. - Common Stock (TNGX)
Tango Therapeutics Inc is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company specializes in understanding the genetic and biological drivers of cancer, utilizing its expertise in synthetic lethality to create targeted treatments that aim to exploit specific vulnerabilities in cancer cells. Tango Therapeutics employs cutting-edge research and drug discovery techniques to identify and develop novel compounds that can improve patient outcomes, emphasizing precision medicine and personalized treatment approaches in oncology. Through their work, they aim to contribute significantly to the advancement of cancer care and the improvement of therapeutic options available to patients. Read More
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option to purchase an aggregate of 240,000 shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall, the Company’s Chief Financial Officer and (ii) a non-qualified stock option to purchase an aggregate of 199,650 shares of its common stock and 33,250 RSUs to a new employee, under Tango Therapeutics' 2023 Inducement Plan.
- Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (NYSE: ABBV) was in advanced discussions
CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.
